CCDC137抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: 293T cell lysate, Primary antibody: P02464(CCDC137 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P02464(CCDC137 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The CCDC137 (Coiled-Coil Domain Containing 137) antibody is a research tool designed to detect and study the CCDC137 protein, a relatively undercharacterized member of the coiled-coil domain-containing protein family. CCDC137 is encoded by the *CCDC137* gene, which is conserved across vertebrates and implicated in diverse cellular processes. While its exact biological function remains unclear, emerging studies suggest potential roles in transcriptional regulation, cell cycle progression, and intracellular signaling. The protein’s coiled-coil domains may mediate protein-protein interactions, influencing pathways relevant to development or disease.

CCDC137 antibodies are typically produced in immunized hosts (e.g., rabbits or mice) using peptide antigens derived from conserved regions of the protein. These antibodies enable researchers to investigate CCDC137 expression patterns, subcellular localization (e.g., nuclear or cytoplasmic), and interactions via techniques like Western blotting, immunohistochemistry, or immunoprecipitation. Some studies link *CCDC137* dysregulation to pathologies, including cancers, where its overexpression or suppression may correlate with tumor progression or patient prognosis. However, comprehensive mechanistic insights are limited, and antibody specificity remains a critical consideration due to potential cross-reactivity with homologous proteins.

Current research focuses on validating CCDC137 antibodies for reliability across experimental models and clarifying the protein’s functional relevance in health and disease. Further characterization of CCDC137 could uncover novel therapeutic targets or biomarkers, driving interest in refining antibody-based detection tools.